Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Change in Cash (2020 - 2025)

Historic Change in Cash for Rani Therapeutics Holdings (RANI) over the last 6 years, with Q3 2025 value amounting to -$6.1 million.

  • Rani Therapeutics Holdings' Change in Cash fell 246202.53% to -$6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$133000.0, marking a year-over-year increase of 8086.33%. This contributed to the annual value of -$2.1 million for FY2024, which is 9005.82% up from last year.
  • Rani Therapeutics Holdings' Change in Cash amounted to -$6.1 million in Q3 2025, which was down 246202.53% from $105000.0 recorded in Q2 2025.
  • Rani Therapeutics Holdings' 5-year Change in Cash high stood at $60.4 million for Q3 2021, and its period low was -$69.5 million during Q3 2022.
  • In the last 5 years, Rani Therapeutics Holdings' Change in Cash had a median value of -$2.4 million in 2024 and averaged -$3.6 million.
  • Per our database at Business Quant, Rani Therapeutics Holdings' Change in Cash soared by 165105.77% in 2021 and then tumbled by 246202.53% in 2025.
  • Quarter analysis of 5 years shows Rani Therapeutics Holdings' Change in Cash stood at -$12.3 million in 2021, then surged by 98.28% to -$212000.0 in 2022, then surged by 520.75% to $892000.0 in 2023, then crashed by 157.74% to -$515000.0 in 2024, then crashed by 1079.03% to -$6.1 million in 2025.
  • Its Change in Cash stands at -$6.1 million for Q3 2025, versus $105000.0 for Q2 2025 and $6.3 million for Q1 2025.